Skip to content

99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis

99mTc-rhAnnexin V-128 Planar and SPECT Imaging of Apoptosis in Asymptomatic Or Previously Symptomatic With TIA Patients With Carotid Atherosclerotic Plaque

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02667457
Enrollment
39
Registered
2016-01-29
Start date
2016-06-23
Completion date
2018-11-19
Last updated
2020-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid Artery Plaque

Keywords

Carotid Stenosis, Carotid Artery Narrowing, Carotid Artery Plaque, Carotid Artery Stenosis, Carotid Artery Ulcerating Plaque, Carotid Ulcer, Common Carotid Artery Stenosis, External Carotid Artery Stenosis, Internal Carotid Artery Stenosis, Plaque, Ulcerating, Carotid Artery, Stenosis, Common Carotid Artery, Stenosis, External Carotid Artery, Ulcerating Plaque, Carotid Artery

Brief summary

This was a single-center, single-dose, study comprising a Proof of Concept (PoC) part and a subsequent Phase II part. The study was being done to assess the ability of the radiotracer 99mTc-rhAnnexin V-128 to image atherosclerotic plaque that might rupture and break off artery walls. This is caused by apoptosis or cell death in the plaque. These ruptured plaques can block blood circulation in the arteries causing a lack of oxygen to the tissues. Atherosclerotic plaques can build up on any artery in the body.

Detailed description

The sponsor decided to terminate the study earlier than planned due to strategic decisions to focus the AAA development portfolio on oncology theragnostics and not based on safety concerns. Novartis acquired Advanced Accelerator Applications SA.

Interventions

Sponsors

Advanced Accelerator Applications
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For all participants: 1. Males and females age 18 years or greater 2. Able and willing to comply with the study procedures 3. Negative pregnancy test for women of childbearing potential at screening and on the day of administration of 99mTc-rhAnnexin V-128. For participants with carotid artery disease: 4. Evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years; 5. Evidence of 50% or more carotid stenosis in the most recent US imaging within 8 weeks prior to 99mTc-rhAnnexin V-128 administration For control participants: 6. No significant carotid artery disease on carotid ultrasound; 7. No clinically significant abnormalities in baseline laboratory values.

Exclusion criteria

1. Previous carotid stending, endarterectomy or stroke; 2. Diagnosis of vasculitis, dissection, or non-atherosclerotic carotid disease (Ehlers-Danlos, Marfans); 3. Pregnancy or lactation; 4. History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment; 5. Know hypersensitivity to the investigational product or any of its components; 6. Claustrophobia or inability to lie still in a supine position; 7. Participation in another clinical trial within 4 weeks before study inclusion, except for patients who have participated or who are currently participating in a study without any study drug administration; 8. Unwillingness to provide consent.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Evaluated for Imaging FeasibilityDay 0The frequency and severity of abnormal carotid scans was determined in the CAD participants and control groups by review of the number, localization, length and uptake intensity grade of each plaque to define a positive or negative scan at each time point. The feasibility of imaging apoptotic activity in CAD using 99mTc-rhAnnexin V-128 was assessed by the data monitoring committee (visual image review and consensus). The three reviewers of the DMC did an independent visual assessment of the images using a 1 to 4 point grading system: each observer reviewed the images of each patient and scored either 1 or 2 (uptake was less than or equal to blood pool), these images were considered normal; 3 was equivocal and four equalled abnormal. Only descriptive analysis performed.
Percentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)At 60 and 120 minutes post injection on Day 0The prevalence of apoptotic activity was defined as the percentage of participants with abnormal Single-Photon Emission Computed Tomography (SPECT) imaging scans (also described as positive scans). The overall result of 99mTc-rhAnnexin V-128 imaging was unique: participants with at least one SPECT imaging as positive result (after 60 min or after 120 min from 99mTc-rhAnnexin V-128 injection) were considered as abnormal, participants with SPECT/CT images as negative were considered as normal. All images were acquired with a dual head SPECT/CT gamma camera with low-energy high-resolution collimators. Only descriptive analysis performed.

Secondary

MeasureTime frameDescription
Ascending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)At 60 and 120 minutes post injection on Day 0Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).
Descending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)At 60 and 120 minutes post injection on Day 0Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).
Aortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)At 60 and 120 minutes post injection on Day 0Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).
Left Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)At 60 and 120 minutes post injection on Day 0Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).
Right Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityAt 60 and 120 minutes post injection on Day 0B-mode and color Doppler ultrasound studies were acquired of both carotid arteries and performed with an ultrasound scanner equipped with a 5- to 7-MHz transducer. Plaque morphology, as echogenicity, defined as reflectance of the emitted ultrasound signal, were assessed and graded from 1 to 4 as echolucent, predominantly echolucent, predominantly echogenic, or echogenic. The vessel lumen was used as the reference structure for defining echolucency, and the bright echo zone produced by the media-adventitia interface in the far wall was used as the reference structure for defining echogenicity. Uptake was reported as the ratio of the uptake in the region of interest (target) to the uptake in the blood pool (background). Only descriptive analysis performed.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathFrom Day 0 post injection up to Day 30An AE is defined as any untoward medical occurrence in a participant and which does not necessarily have a causal relationship with the investigational product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease, temporally associated with the use of an investigational product, whether or not causally related to the investigational product. Treatment emergent adverse events that emerge after the 99mTc-rhAnnexin V-128 injection and up to 30 days after the injection that were absent before it or worsen relative to the pre-treatment state. A serious AE is defined as any untoward medical occurrence that at any dose results in death; is life-threatening; results in persistent or significant disability or incapacity; results in congenital anomaly or birth defect; or requires inpatient hospitalization or prolongation of hospitalization. Only descriptive analysis performed.
Number of Participants With Clinically Significant Abnormal Laboratory ValuesFrom Day 0 post injection up to Day 30Laboratory data was analysed with respect to the normal ranges of values provided by the local laboratory and with respect to levels of change and significance in these values. The evaluation of the Clinically Significant Abnormal Laboratory Values was at the discretion of the Principal Investigator and noted as such in patient files, where necessary. Participants with abnormal laboratory values were analyzed based on clinical relevance. Only descriptive analysis performed.
Left Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityAt 60 and 120 minutes post injection on Day 0B-mode and color Doppler ultrasound studies were acquired of both carotid arteries and performed with an ultrasound scanner equipped with a 5- to 7-MHz transducer. Plaque morphology, as echogenicity, defined as reflectance of the emitted ultrasound signal, were assessed and graded from 1 to 4 as echolucent, predominantly echolucent, predominantly echogenic, or echogenic. The vessel lumen was used as the reference structure for defining echolucency, and the bright echo zone produced by the media-adventitia interface in the far wall was used as the reference structure for defining echogenicity. Uptake was reported as the ratio of the uptake in the region of interest (target) to the uptake in the blood pool (background). Only descriptive analysis performed.
Right Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)At 60 and 120 minutes post injection on Day 0Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Countries

Canada

Participant flow

Recruitment details

The study was conducted at single center in Canada.

Pre-assignment details

A total of 39 participants were screened and enrolled to the study, of which only 36 participants were administered with investigational imaging product. All 36 treated participants completed the study.

Participants by arm

ArmCount
CAD Participants
Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on Day 0.
26
Healthy Participants
Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on Day 0.
10
Total36

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyOther Reason02
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicHealthy ParticipantsTotalCAD Participants
Age, Continuous58.4 years
STANDARD_DEVIATION 12.1
67.4 years
STANDARD_DEVIATION 10.1
70.9 years
STANDARD_DEVIATION 6.6
Race/Ethnicity, Customized
Caucasian
9 Participants35 Participants26 Participants
Race/Ethnicity, Customized
Other
1 Participants1 Participants0 Participants
Sex: Female, Male
Female
5 Participants10 Participants5 Participants
Sex: Female, Male
Male
5 Participants26 Participants21 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 260 / 10
other
Total, other adverse events
7 / 260 / 10
serious
Total, serious adverse events
1 / 260 / 10

Outcome results

Primary

Number of Participants Evaluated for Imaging Feasibility

The frequency and severity of abnormal carotid scans was determined in the CAD participants and control groups by review of the number, localization, length and uptake intensity grade of each plaque to define a positive or negative scan at each time point. The feasibility of imaging apoptotic activity in CAD using 99mTc-rhAnnexin V-128 was assessed by the data monitoring committee (visual image review and consensus). The three reviewers of the DMC did an independent visual assessment of the images using a 1 to 4 point grading system: each observer reviewed the images of each patient and scored either 1 or 2 (uptake was less than or equal to blood pool), these images were considered normal; 3 was equivocal and four equalled abnormal. Only descriptive analysis performed.

Time frame: Day 0

Population: Full Analysis Set population (FAS)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CAD ParticipantsNumber of Participants Evaluated for Imaging Feasibility15 Participants
Healthy ParticipantsNumber of Participants Evaluated for Imaging Feasibility5 Participants
Primary

Percentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)

The prevalence of apoptotic activity was defined as the percentage of participants with abnormal Single-Photon Emission Computed Tomography (SPECT) imaging scans (also described as positive scans). The overall result of 99mTc-rhAnnexin V-128 imaging was unique: participants with at least one SPECT imaging as positive result (after 60 min or after 120 min from 99mTc-rhAnnexin V-128 injection) were considered as abnormal, participants with SPECT/CT images as negative were considered as normal. All images were acquired with a dual head SPECT/CT gamma camera with low-energy high-resolution collimators. Only descriptive analysis performed.

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set population (FAS)

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionPositive (abnormal)8 Participants
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionMissing0 Participants
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionNegative (normal)16 Participants
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionMissing1 Participants
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionPositive (abnormal)8 Participants
CAD ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionNegative (normal)17 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionPositive (abnormal)0 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionMissing0 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionMissing0 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionPositive (abnormal)0 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)120 mins after injectionNegative (normal)10 Participants
Healthy ParticipantsPercentage of Participants With Prevalence of Abnormal 99mTc-rhAnnexin V-128 SPECT/CT Imaging (Phase II Step)60 mins after injectionNegative (normal)10 Participants
Secondary

Aortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)

Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with Aortic Arch Uptake Correlation Imaging Assessment included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsAortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.986 Target to Background Ratio (TBR)Standard Deviation 0.679
CAD ParticipantsAortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.628 Target to Background Ratio (TBR)Standard Deviation 0.38
Healthy ParticipantsAortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.606 Target to Background Ratio (TBR)Standard Deviation 0.279
Healthy ParticipantsAortic Arch Uptake Correlation Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.294 Target to Background Ratio (TBR)Standard Deviation 0.174
Comparison: Timepoint = 60 minutesp-value: 0.0359t-test, 1 sided
Comparison: Timepoint = 120 minutesp-value: 0.0022t-test, 1 sided
Secondary

Ascending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)

Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with Ascending Aorta Uptake Imaging Assessment included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsAscending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes2.054 Target to Background Ratio (TBR)Standard Deviation 0.656
CAD ParticipantsAscending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.616 Target to Background Ratio (TBR)Standard Deviation 0.294
Healthy ParticipantsAscending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.574 Target to Background Ratio (TBR)Standard Deviation 0.252
Healthy ParticipantsAscending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.381 Target to Background Ratio (TBR)Standard Deviation 0.19
Comparison: Timepoint = 60 minutesp-value: 0.0066t-test, 1 sided
Comparison: Timepoint = 120 minutesp-value: 0.0301t-test, 1 sided
Secondary

Descending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)

Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with Descending Aorta Uptake Imaging Assessment included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsDescending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes2.159 Target to Background Ratio (TBR)Standard Deviation 0.865
CAD ParticipantsDescending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.520 Target to Background Ratio (TBR)Standard Deviation 0.245
Healthy ParticipantsDescending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.590 Target to Background Ratio (TBR)Standard Deviation 0.164
Healthy ParticipantsDescending Aorta Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.341 Target to Background Ratio (TBR)Standard Deviation 0.131
Comparison: Timepoint = 60 minutesp-value: 0.0066t-test, 1 sided
Comparison: Timepoint = 120 minutesp-value: 0.0387t-test, 1 sided
Secondary

Left Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/Echogenicity

B-mode and color Doppler ultrasound studies were acquired of both carotid arteries and performed with an ultrasound scanner equipped with a 5- to 7-MHz transducer. Plaque morphology, as echogenicity, defined as reflectance of the emitted ultrasound signal, were assessed and graded from 1 to 4 as echolucent, predominantly echolucent, predominantly echogenic, or echogenic. The vessel lumen was used as the reference structure for defining echolucency, and the bright echo zone produced by the media-adventitia interface in the far wall was used as the reference structure for defining echogenicity. Uptake was reported as the ratio of the uptake in the region of interest (target) to the uptake in the blood pool (background). Only descriptive analysis performed.

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with left carotid with stenosis \>=50% are taken into account.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEchogenic: 120 Minutes1.387 RatioStandard Deviation 0.496
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echogenic: 120 Minutes1.096 RatioStandard Deviation 0.186
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEchogenic: 60 Minutes0.950 RatioStandard Deviation 0.245
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echolucent: 60 Minutes1.490 RatioStandard Deviation 0.756
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echolucent: 120 Minutes1.014 RatioStandard Deviation 0.309
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echogenic: 60 Minutes0.945 RatioStandard Deviation 0.287
UnknownLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEcholucent: 120 Minutes Ratio
UnknownLeft Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEcholucent: 60 Minutes Ratio
Secondary

Left Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)

Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with Left Carotid Uptake Imaging Assessment included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.171 Target to Background Ratio (TBR)Standard Deviation 0.764
CAD ParticipantsLeft Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.208 Target to Background Ratio (TBR)Standard Deviation 0.486
Healthy ParticipantsLeft Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes0.697 Target to Background Ratio (TBR)Standard Deviation 0.222
Healthy ParticipantsLeft Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes0.827 Target to Background Ratio (TBR)Standard Deviation 0.205
Comparison: Timepoint = 60 minutesp-value: 0.0095t-test, 1 sided
Comparison: Timepoint = 120 minutesp-value: 0.0029t-test, 1 sided
Secondary

Number of Participants With Clinically Significant Abnormal Laboratory Values

Laboratory data was analysed with respect to the normal ranges of values provided by the local laboratory and with respect to levels of change and significance in these values. The evaluation of the Clinically Significant Abnormal Laboratory Values was at the discretion of the Principal Investigator and noted as such in patient files, where necessary. Participants with abnormal laboratory values were analyzed based on clinical relevance. Only descriptive analysis performed.

Time frame: From Day 0 post injection up to Day 30

Population: Safety Population Set. Only participants with abnormal laboratory values are taken into account.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesBlood ChemistryAbnormal non clinical relevant26 Participants
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesUrinalysisAbnormal non clinical relevant10 Participants
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesBlood ChemistryAbnormal clinically relevant0 Participants
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesHematologyAbnormal non clinical relevant15 Participants
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesHematologyAbnormal clinically relevant0 Participants
CAD ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesUrinalysisAbnormal clinically relevant0 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesHematologyAbnormal clinically relevant0 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesBlood ChemistryAbnormal clinically relevant0 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesHematologyAbnormal non clinical relevant4 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesUrinalysisAbnormal non clinical relevant4 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesBlood ChemistryAbnormal non clinical relevant10 Participants
Healthy ParticipantsNumber of Participants With Clinically Significant Abnormal Laboratory ValuesUrinalysisAbnormal clinically relevant0 Participants
Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and Death

An AE is defined as any untoward medical occurrence in a participant and which does not necessarily have a causal relationship with the investigational product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease, temporally associated with the use of an investigational product, whether or not causally related to the investigational product. Treatment emergent adverse events that emerge after the 99mTc-rhAnnexin V-128 injection and up to 30 days after the injection that were absent before it or worsen relative to the pre-treatment state. A serious AE is defined as any untoward medical occurrence that at any dose results in death; is life-threatening; results in persistent or significant disability or incapacity; results in congenital anomaly or birth defect; or requires inpatient hospitalization or prolongation of hospitalization. Only descriptive analysis performed.

Time frame: From Day 0 post injection up to Day 30

Population: Safety Population Set

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Serious Adverse Drug Reactions0 Participants
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Adverse Events (TEAEs)7 Participants
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTEAEs leading to Withdrawal0 Participants
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Serious Adverse Events (TESAEs)1 Participants
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTEAEs leading to Deaths0 Participants
CAD ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Adverse Drug Reactions2 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTEAEs leading to Deaths0 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Adverse Events (TEAEs)0 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Adverse Drug Reactions0 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Serious Adverse Events (TESAEs)0 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTreatment Emergent Serious Adverse Drug Reactions0 Participants
Healthy ParticipantsNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and DeathTEAEs leading to Withdrawal0 Participants
Secondary

Right Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/Echogenicity

B-mode and color Doppler ultrasound studies were acquired of both carotid arteries and performed with an ultrasound scanner equipped with a 5- to 7-MHz transducer. Plaque morphology, as echogenicity, defined as reflectance of the emitted ultrasound signal, were assessed and graded from 1 to 4 as echolucent, predominantly echolucent, predominantly echogenic, or echogenic. The vessel lumen was used as the reference structure for defining echolucency, and the bright echo zone produced by the media-adventitia interface in the far wall was used as the reference structure for defining echogenicity. Uptake was reported as the ratio of the uptake in the region of interest (target) to the uptake in the blood pool (background). Only descriptive analysis performed.

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with right carotid with stenosis \>=50% are taken into account.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEcholucent: 60 Minutes0.619 RatioStandard Deviation 0
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEcholucent: 120 Minutes0.820 RatioStandard Deviation 0
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echolucent: 60 Minutes0.955 RatioStandard Deviation 0.192
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echogenic: 60 Minutes1.593 RatioStandard Deviation 1.174
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echogenic: 120 Minutes1.294 RatioStandard Deviation 0.851
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityPredominantly echolucent: 120 Minutes1.126 RatioStandard Deviation 0.311
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEchogenic: 60 Minutes1.180 RatioStandard Deviation 0.206
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measure by Target to Background Ratio (TBR) by Ultrasound Grade of Plaque Echolucency/EchogenicityEchogenic: 120 Minutes1.149 RatioStandard Deviation 0.438
Secondary

Right Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)

Quantitative analysis of planar images was carried out by placing a region of interest in the carotid areas and over a background area placed in the subclavian regions representing venous and arterial activity (target-to-background). Carotid artery uptake measured as TBR data for right and left carotids at 1 and 2 hours was compared between normal control and carotid artery disease groups. Quantitative analysis of the SPECT 1 and 2 hour images was done with regions of interest placed over the arterial target (right carotid, left carotid, ascending aorta, arch and descending aorta) and adjacent vein (internal jugular, SVC or IVS) using transaxial slices. TBR was calculated as arterial max / venous mean (the average of 3 slices centered on the slice with the highest TBR value).

Time frame: At 60 and 120 minutes post injection on Day 0

Population: Full Analysis Set (FAS). Only participants with Right Carotid Uptake Imaging Assessment included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes1.220 Target to Background Ratio (TBR)Standard Deviation 0.55
CAD ParticipantsRight Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes1.252 Target to Background Ratio (TBR)Standard Deviation 0.745
Healthy ParticipantsRight Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)60 Minutes0.768 Target to Background Ratio (TBR)Standard Deviation 0.209
Healthy ParticipantsRight Carotid Uptake Imaging Assessment as Measured by Target to Background Ratio (TBR)120 Minutes0.928 Target to Background Ratio (TBR)Standard Deviation 0.217
Comparison: Timepoint = 60 minutesp-value: 0.0066t-test, 1 sided
Comparison: Timepoint = 120 minutesp-value: 0.0334t-test, 1 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026